
Regeneron's Livsayis (cemdisiran) gains FDA approval for adults with antibody-positive generalized myasthenia gravis, dosed four times a year.
The European CRO industry is becoming more competitive and complex by the day. What will it take to remain successful in this rapidly evolving landscape? Alan Morgan investigates.






